News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
9,580 Results
Type
Article (990)
Company Profile (1)
Press Release (8589)
Section
Business (3354)
Career Advice (16)
Deals (501)
Drug Delivery (2)
Drug Development (1438)
Employer Resources (7)
FDA (291)
Job Trends (408)
News (5566)
Policy (521)
Tag
Academia (35)
Allergies (1)
Alliances (1013)
ALS (2)
Alzheimer's disease (4)
Antibody-drug conjugate (ADC) (3)
Approvals (297)
Artificial intelligence (5)
Autoimmune disease (1)
Bankruptcy (4)
Best Places to Work (331)
BIOSECURE Act (2)
Biosimilars (7)
Biotechnology (2)
Breast cancer (3)
Cancer (32)
Cardiovascular disease (8)
Career advice (16)
CAR-T (2)
Cell therapy (5)
Cervical cancer (1)
Clinical research (1228)
Collaboration (20)
Compensation (2)
Complete response letters (1)
COVID-19 (43)
CRISPR (4)
C-suite (8)
Data (31)
Diabetes (3)
Diagnostics (27)
Diversity, equity & inclusion (3)
Drug discovery (2)
Earnings (790)
Editorial (1)
Employer branding (5)
Employer resources (7)
Events (952)
Executive appointments (19)
FDA (311)
Funding (18)
Gene editing (5)
Generative AI (2)
Gene therapy (11)
GLP-1 (13)
Government (66)
Guidances (1)
Healthcare (144)
Infectious disease (43)
Intellectual property (1)
IPO (174)
Job creations (92)
Job search strategy (13)
Labor market (1)
Layoffs (34)
Leadership (1)
Legal (138)
Liver cancer (8)
Lung cancer (4)
Lymphoma (1)
Manufacturing (1)
Medical device (51)
Medtech (51)
Mergers & acquisitions (334)
Metabolic disorders (8)
Neuroscience (9)
NextGen: Class of 2025 (70)
Non-profit (33)
Northern California (43)
Obesity (4)
Opinion (6)
Parkinson's disease (2)
Patents (1)
Peanut (1)
People (1363)
Pharmaceutical (1)
Phase I (333)
Phase II (393)
Phase III (603)
Pipeline (15)
Podcasts (8)
Policy (3)
Postmarket research (95)
Preclinical (82)
Prostate cancer (8)
Radiopharmaceuticals (6)
Rare diseases (5)
Real estate (86)
Recruiting (2)
Regulatory (359)
Reports (3)
Research institute (29)
Resumes & cover letters (3)
Schizophrenia (1)
Series A (2)
Series B (3)
Sickle cell disease (1)
Southern California (27)
Special edition (1)
Startups (86)
The Weekly (8)
United States (258)
Vaccines (3)
Venture capitalists (3)
Weight loss (4)
Women's health (5)
Date
Last 7 days (4)
Last 30 days (30)
Last 365 days (454)
2025 (81)
2024 (472)
2023 (461)
2022 (1106)
2021 (981)
2020 (851)
2019 (670)
2018 (391)
2017 (506)
2016 (454)
2015 (521)
2014 (357)
2013 (318)
2012 (345)
2011 (391)
2010 (310)
Location
Africa (13)
Arizona (2)
Asia (571)
Australia (76)
California (77)
Canada (5)
China (9)
Colorado (2)
Connecticut (5)
Europe (2317)
Florida (1)
Hawaii (1)
Idaho (2)
Indiana (3)
Japan (2)
Kansas (2)
Louisiana (1)
Maryland (11)
Massachusetts (54)
Michigan (1)
Minnesota (4)
Missouri (4)
New Jersey (17)
New York (62)
North Carolina (10)
Northern California (43)
Ohio (1)
Pennsylvania (5)
Puerto Rico (1)
South America (17)
Southern California (27)
Texas (2)
Utah (5)
Washington State (1)
9,580 Results for "bayer".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Postmarket research
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
December 17, 2024
·
2 min read
·
Tristan Manalac
Clinical research
Bayer’s Kidney Disease Drug Kerendia Reduces Cardiovascular Risk by 16%
Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.
September 3, 2024
·
2 min read
·
Annalee Armstrong
Layoffs
Bayer to Lay Off 150 in Basel, Switzerland
The Switzerland layoffs are the latest in Bayer’s 2024 workforce reductions, which already include 1,500 people and nearly half of the executive leadership team.
August 26, 2024
·
1 min read
·
Angela Gabriel
Earnings
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged investors to be patient as the company executes on a performance-boosting strategy outlined in March.
November 12, 2024
·
2 min read
·
Annalee Armstrong
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
January 14, 2025
·
11 min read
Layoffs
Bayer, J&J and Pfizer to Lay Off Nearly 500 Combined Employees
Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland. Many of the layoffs are effective by the end of the year.
October 2, 2024
·
3 min read
·
Angela Gabriel
Drug Development
Bayer’s Finerenone Hits Primary Endpoint in Phase III Heart Failure Trial
With the late-stage win, Bayer announced Monday that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.
August 5, 2024
·
2 min read
·
Nick Paul Taylor
Earnings
Bayer Touts ‘Modest’ Q2 Performance Amid Sweeping Reorganization
Bayer’s surprising growth in the second quarter was driven in large part by two pharma products: the prostate cancer drug Nubeqa and the chronic kidney disease treatment Kerendia.
August 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
January 10, 2025
·
7 min read
1 of 958
Next
